·é¼ö¹Ì¿À(LUNSUMIO) ½Å¾à ÀλçÀÌÆ®¿Í ½ÃÀå ¿¹Ãø(2032³â)
LUNSUMIO Emerging Drug Insight and Market Forecast - 2032
»óǰÄÚµå : 1397394
¸®¼­Ä¡»ç : DelveInsight Business Research LLP
¹ßÇàÀÏ : 2023³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 30 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,485,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,875 £Ü 6,728,000
PDF (2-3 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 3¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,500 £Ü 8,971,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 9,750 £Ü 13,456,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸ñÂ÷

Á¦1Àå ¸®Æ÷Æ®ÀÇ ¼­·Ð

Á¦2Àå DLBCL¿¡¼­ ·é¼ö¹Ì¿À(LUNSUMIO)ÀÇ °³¿ä

Á¦3Àå °æÀï ±¸µµ(Ãâ½Ã Ä¡·á¹ý)

Á¦4Àå °æÀï ±¸µµ(Èı⠽ÅÄ¡·á¹ý)

Á¦5Àå ·é¼ö¹Ì¿À(LUNSUMIO) ½ÃÀå Æò°¡

Á¦6Àå SWOT ºÐ¼®

Á¦7Àå ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ

Á¦8Àå ºÎ·Ï

Á¦9Àå DelveInsightÀÇ ¼­ºñ½º ³»¿ë

Á¦10Àå ¸éÃ¥»çÇ×

Á¦11Àå DelveInsight ¼Ò°³

Á¦12Àå ¸®Æ÷Æ® ±¸ÀÔ ¿É¼Ç

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

"LUNSUMIO Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about LUNSUMIO for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets. A detailed picture of the LUNSUMIO for DLBCL in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the LUNSUMIO for DLBCL. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LUNSUMIO market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.

Drug Summary:

LUNSUMIO (mosunetuzumab, RG7828) is a first-in-class CD20 x CD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. This dual targeting activates and redirects a patient's existing T cells to engage and eliminate target B cells by releasing cytotoxic proteins into the B cells. A robust clinical development program for LUNSUMIO is ongoing, investigating the molecule as a monotherapy and in combination with other medicines for treating people with B-cell NHL, including FL, DLBCL, and other blood cancers.

In July 2022, Roche announced that the US FDA accepted the company's Biologics License Application (BLA) and granted Priority Review for LUNSUMIO to treat adults with R/R FL who have received at least two prior systemic therapies.

Currently, Roche is investigating the LUNSUMIO plus POLIVY in Phase III (SUNMO) trial in 2L DLBCL, with most trial locations outside the 7MM except for Japan. With an expected submission in the US by 2025 and beyond and by 2024 in Japan, as per Chugai Pharmaceutical.

Scope of the Report:

The report provides insights into:

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LUNSUMIO Analytical Perspective by DelveInsight

In-depth LUNSUMIO Market Assessment

This report provides a detailed market assessment of LUNSUMIO for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

LUNSUMIO Clinical Assessment

The report provides the clinical trials information of LUNSUMIO for DLBCL covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

Key Questions:

Table of Contents

1. Report Introduction

2. LUNSUMIO Overview in DLBCL

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. LUNSUMIO Market Assessment

6. SWOT Analysis

7. Analysts' Views

8. Appendix

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â